Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?
Approach · directive: “why / how”
What it asks · Explain why biotechnology has grown so fast in India (skills, policy, demand) and how that has helped biopharma: vaccines, biosimilars and low-cost drugs.
The question has 2 parts — answer each
- Why: reasons for the high level of biotechnology activity in India — skills, industry base, demand and policy
- How: how this activity has benefited biopharma — vaccines, biosimilars, affordable drugs and exports, with the remaining challenges
Open with · India combines a large scientific workforce, a strong pharma base, big health and farm needs and supportive policy, which has made biotechnology one of its fastest-growing knowledge sectors.
Cover
- Drivers: a large pool of trained scientists and low-cost research, rich biodiversity, an established generic pharma industry, and big needs in health, food and energy.
- Policy push: the Department of Biotechnology (1986), the National Biotechnology Development Strategy (2015-20), BIRAC (2012) for start-ups and industry, incubators and biotech parks, and Make in India.
- Farm and industrial biotech: Bt cotton since 2002, biofertilisers and biopesticides, tissue culture, enzymes and biofuels, though the debate on genetically modified crops continues.
- Biopharma gains: India is a leading vaccine maker; indigenous vaccines such as Rotavac, affordable insulin, monoclonal antibodies, biosimilars and diagnostics lower prices and support exports.
- Regulation and IPR: product patents since 2005 pushed firms towards innovation; guidelines on similar biologics (2012, revised 2016) opened the biosimilar route.
- Challenges: thin early-stage funding, slow approvals, imported inputs and equipment, weak translational research, biosafety and the ethics of clinical trials.
Close with · India's biotech surge rests on skills, policy and demand; sustaining biopharma's gains needs more research funding, faster regulation and strong IPR and biosafety frameworks.
Question: UPSC's CS (Main) 2018, GS Paper III — paper ↗. Approach: Minimalist IAS, checked 30 Sept 2026 (how we verify) — UPSC publishes no model answers. ·
Model answer · 279 words (UPSC limit 250) · Minimalist IAS
India pairs a large scientific workforce and a strong generic-pharma base with big needs in health, food and energy and a supportive policy framework; together these have made biotechnology one of its fastest-growing knowledge sectors.
Why so much activity
- People and cost: a large pool of trained biologists, chemists and engineers, and research at a fraction of Western cost.
- Industry base: an established generic pharmaceutical industry with manufacturing scale and regulatory experience, ready to move into biologics.
- Demand: a large disease burden, the need for affordable vaccines and drugs, food security and biofuels create domestic markets.
- Policy: the Department of Biotechnology (1986), the National Biotechnology Development Strategy 2015-20, BIRAC (2012) funding start-ups and industry-academia projects, biotech parks and incubators, and Make in India.
- Resources and farm use: rich biodiversity; Bt cotton since 2002, biofertilisers, biopesticides and tissue culture, though the debate on GM food crops continues.
- IPR: product patents since 2005 pushed firms from copying towards innovation.
How biopharma has benefited
- Vaccines: India is a leading vaccine maker for the world; indigenous products such as Rotavac show research-to-market capability.
- Biosimilars: guidelines on similar biologics (2012, revised 2016) opened a regulated path; Indian firms make affordable insulin and monoclonal antibodies, cutting prices at home and building exports.
- Diagnostics and enzymes: low-cost diagnostic kits and industrial enzymes widen access and lower healthcare costs.
- Ecosystem: BIRAC grants and incubators have created a pipeline of biopharma start-ups.
Challenges
- Thin early-stage funding, slow approvals, dependence on imported inputs and equipment, weak translational research, and biosafety and clinical-trial ethics.
India's biotech surge rests on skills, policy and demand; sustaining biopharma's gains needs more research funding, faster and predictable regulation, and strong IPR and biosafety frameworks.
Written by Minimalist IAS from facts checked at source (how we verify) — a little fuller than exam length, so every part of the question is covered; in the hall, keep the structure and trim the detail. UPSC publishes no model answers: compare your structure and coverage with this, then write your own.